183 results about "Allopurinol" patented technology

The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly SJS or TEN. It was discovered that an HLA-B allele, HLA-B* 1502, is associated with SJS / TEN that is induced by a variety of drugs. The correlation with HLA-B* 1502 is most significant for carbamazepine-induced SJS / TEN, wherein all the patients tested have the HLA-B* 1502 allele. In addition, another HLA-B allele, HLA-B*5801, is particularly associated with SJS / TEN induced by allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythema multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-B *4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphism markers) located between DRB1 and HLA-A region of the specific HLA-B haplotype can also be used for the test.

The invention belongs to the field of pharmacogenomics and genetic diagnosis, and relates to a method used for detecting HLA-B*5801 alleles. The method comprises following steps: a DNA sample to be detected is taken, three pairs of specific primers and a pair of internal primers are taken, amplification of DNA segments is realized by using sequence specific primer method, and then the results of the amplification are analyzed by agarose gel electrophoresis; or sample DNA is extracted, a pair of specific primers, a pair of internal primers and three fluorescence probes are taken, amplification of DNA segments is realized by Taqman probe method using a fluorescence ration PCR instrument, and then the amplification curve is analyzed so as to obtain results. Results analysis methods such as agarose gel electrophoresis, high resolution melting curve and SYBRGreen fluorogenic quantitative PCR are employed in the method. The method has advantages of speediness, convenience, flexibility, high resolution and no contamination; is suitable for detection of HLA-B*5801 alleles in samples such as peripheral blood and hair; and can be used for determining the probability of severe skin adverse reaction of patients with gout or hyperuricemia caused by taking of allopurinol.

The invention relates to the technical field of medicine, in particular to an allopurinol sustained-release pellet, and a preparation method and a preparation thereof. The allopurinol sustained-release pellet comprises the following components in parts by weight: 30-95 parts of allopurinol and 1-20 parts of anionic polymer, and further comprises a diluent or a pellet core. According to the allopurinol sustained-release pellet, the anionic polymer serves as both an adhesive and a sustained release material, and no additional adhesive is needed, so that the types and consumption of auxiliary materials are reduced, and the relative content of allopurinol in the pellet is improved. In addition, as the anionic polymer is applied in the pellet skeleton, the step of coating the sustained-release material is omitted, and accordingly, the preparation steps are reduced. Therefore, the allopurinol sustained-release pellet simplified not only the formula but also the preparation technology.

Evidence is presented that inflammation and injury involves activation of xanthine oxidoreductase (XOR) in the newly recruited mononuclear phagocytes (MNP). XOR has been shown to be increased predominantly in the MNP that increase rapidly in the lungs of rats that develop acute lung injury (ALI) following intratracheal cytokine insufflation. XOR was recovered from the MNP largely converted to its oxygen radical generating, reversible O-form, and alveolar MNP exhibited increased oxidative stress as evidenced by increased nitrotyrosine staining. Cytokine insufflation also increased alveolar cell apoptosis. A functional role for XOR in cytokine induced inflammation was demonstrated. Tungsten and allopurinol decreased MNP XOR induction, nitrotyrosine staining, inflammatory cell infiltration, and alveolar cell apoptosis. Transfer of control or allopurinol treated MNP into rat lungs and confirmed a specific role for MNP XOR in promoting lung inflammation. These data indicate that XOR can contribute to lung inflammation by its expression and conversion in a highly mobile inflammatory cell population.

The invention discloses a composition with rhizoma alpiniae officinarum extract, flos chrysanthemi extract and a uric acid reducing function and application of the composition. The composition is a compound of the rhizoma alpiniae officinarum extract and the flos chrysanthemi extract. The rhizoma alpiniae officinarum extract is made of dry rhizoma alpiniae officinarum and is prepared by the aid ofultrasonic auxiliary ethanol extraction methods and macroporous resin separation and enrichment methods, and diphenylheptane and flavone compounds in the rhizoma alpiniae officinarum are pertinentlyextracted; the flos chrysanthemi extract is made of dry Bo flos chrysanthemi, Qi flos chrysanthemi and Jinsihuang flos chrysanthemi and is prepared by the aid of ethanol reflux extraction methods, andflavone substances in the flos chrysanthemi are pertinently extracted. The composition and the application have the advantages that the composition contains the abundant diphenylheptane compounds (more than 30%) and the abundant flavone (more than 7%) compounds, and is obvious in uric acid reducing activity (the in-vitro xanthine oxidase inhibitory activity is higher than 75 micro-mol of allopurinol equivalent weight / g); the composition has excellent flavor, is safe and reliable and can be applied to hyperuricemia prevention and adjuvant therapy healthcare foods or medicines, and raw materials for the composition are easily available.

The invention discloses a compound with an effect of treating and preventing hyperuricemia or gout and a preparation method as well as application thereof. The general structural formula of the compound is shown as a formula (I); the proportion of lesinuard and an allopurinol medicament can be effectively controlled by the series of the compounds, the dose and frequency are reduced, the effect of combination medication can be achieved by single-time medication, meanwhile the preparation process can be simplified, and the production cost is saved; since a linking group exists between the two compounds, the compound can only be hydrolyzed into two medicaments under the action of an enzyme for a certain time after the compound is orally taken and absorbed; thus, the half-life in vivo of the compound is increased by the process, namely the medicament achieve a slow release effect through a chemical coupling method.

The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly SJS or TEN. It was discovered that an HLA-B allele, HLA-B* 1502, is associated with SJS / TEN that is induced by a variety of drugs. The correlation with HLA-B* 1502 is most significant for carbamazepine-induced SJS / TEN, wherein all the patients tested have the HLA-B* 1502 allele. In addition, another HLA-B allele, HLA-B*5801, is particularly associated with SJS / TEN induced by allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythema multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-B *4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphism markers) located between DRB 1 and HLA-A region of the specific HLA-B haplotype can also be used for the test.

The invention discloses a liver preservation solution which contains the following components in per 100ml: 7-8g of 1,6-fructose diphosptate, 1-2g of glutathione, 2-3g of allopurinol, 0.3-0.5g of traditional Chinese medicine ligustrazine, 8-12mg of traditional Chinese medicine anisodamine and the balance of Ringer's solution added to 100ml. Proved by a large number of experiments, the liver preservation solution has a statistical meaning compared with an experiment contrast group, and two treatment groups (a group of the invention and an American UW treatment group) do not have the statistical meaning. The invention provides an excellent guarantee for long-acting liver preservation, has simple prescription and saves production and inspection cost for production and clinical application.

The invention relates to an allopurinol sustained release pellet, which does not need to adopt special equipment, and comprises allopurinol, sustained release material and hydrophobicbase with the mass ratio of 1%-50%. The hydrophobicbase can adjust the drug release, concretely, after the sustained release pellet enters the body, the sustained release pellet is limited due to the entering of water, so the drug release is slowed down, and the function of retarding the drug release is played.

The invention relates to the field of medicines, and particularly discloses application of 5,6,7,4'-tetrahydroxy flavone and derivatives thereof in preparation of drugs for preventing and treating hyperuricemia and gout. The invention also provides capsules and sustained-release tablets for preventing and treating hyperuricemia and gout. The invention discovers that 5,6,7,4'-tetrahydroxy flavone and derivatives thereof have strong anti-gout action, can significantly reduce the serum uric acid level of mouse suffering from hyperuricemia at low dosage, have activity equivalent to that of allopurinol, have low toxic and side effects, have safety higher than that of anti-gout drugs such as colchicine, allopurinol and anturan used clinically at present, can be used for preparing drugs for preventing and treating hyperuricemia and gout, and have broad clinical application prospects.